{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:52:56Z","timestamp":1791499976336,"version":"4.3.4"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T00:00:00Z","timestamp":1788134400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease strongly associated with obesity and diabetes mellitus type 2 (T2D). GLP-1 receptor agonists (GLP-1RAs) and tirzepatide are increasingly used for metabolic control, but their systemic effects in HS remain poorly characterized.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To compare all-cause mortality, cardiovascular, rheumatologic, metabolic, psychiatric, and non-communicable inflammatory outcomes in HS patients with T2D or obesity treated with GLP-1RAs\/tirzepatide vs. alternative metabolic medications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective cohort study used the US Collaborative Network in TriNetX. Adults (\u226518 years) with HS and T2D or obesity were included, excluding prior bariatric surgery. Exposed patients received a GLP-1RA or tirzepatide for at least one year, controls received other systemic antidiabetic or anti-obesity agents. Outcomes over a 2-year follow-up were assessed using 1:1 propensity score matching (PSM) for each outcome category. Outcomes included all-cause mortality, cardiovascular, rheumatologic, metabolic, psychiatric, and non-communicable inflammatory events. Hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated, and Cox regression was used to confirm significant findings. Sensitivity analyses and benchmark comparisons were performed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Before matching, 8,564 patients received GLP-1RA\/tirzepatide and 6,299 alternative therapies. After matching, GLP-1RA\/tirzepatide use was associated with reduced all-cause mortality (HR: 0.24, 95% CI: 0.145\u20130.395;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&amp;lt;\u20090.0001) and major adverse cardiovascular events (MACE) (HR: 0.61, 95% CI: 0.500\u20130.749;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&amp;lt;\u20090.0001). Risks of stroke and heart failure were also reduced (both\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&amp;lt;\u20090.05). Psychiatric outcomes, including depression (HR: 0.78), suicidal ideation (HR: 0.38), and substance use disorder (HR: 0.58), were significantly reduced (all\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&amp;lt;\u20090.05). Risks for rheumatologic and non-communicable chronic inflammatory outcomes were similar among groups. A modest increase in the risk of hyperlipidemia (HR: 1.25), metabolic dysfunction-associated steatotic liver disease (MASLD) (HR: 1.37), and nausea\/vomiting (HR: 1.31) was observed in the GLP-1RA\/tirzepatide group compared with alternative therapies (all\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&amp;lt;\u20090.05).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>GLP-1RAs and tirzepatide are associated with reduced mortality, cardiovascular and psychiatric morbidity in HS patients with obesity or T2D, without increasing rheumatologic or inflammatory risk. These results extend the systemic benefits of GLP-1RAs and tirzepatide beyond metabolic control and suggest potential therapeutic value in HS.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1909537","type":"journal-article","created":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T04:29:46Z","timestamp":1788150586000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Glucagon-like peptide-1 receptor agonists and tirzepatide are associated with reduced mortality, cardiovascular, and psychiatric risks in patients with hidradenitis suppurativa and type 2 diabetes and\/or obesity: a retrospective cohort study"],"prefix":"10.3389","volume":"13","author":[{"given":"Inga C.","family":"Brouer","sequence":"first","affiliation":[{"name":"Institute for Inflammation Medicine, University of L\u00fcbeck","place":["L\u00fcbeck, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aida","family":"Zani","sequence":"additional","affiliation":[{"name":"Institute for Inflammation Medicine, University of L\u00fcbeck","place":["L\u00fcbeck, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henning","family":"Olbrich","sequence":"additional","affiliation":[{"name":"L\u00fcbeck Institute of Experimental Dermatology, University of L\u00fcbeck and University Clinic of Schleswig-Holstein","place":["L\u00fcbeck, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf J.","family":"Ludwig","sequence":"additional","affiliation":[{"name":"Institute for Inflammation Medicine, University of L\u00fcbeck","place":["L\u00fcbeck, Germany"]},{"name":"L\u00fcbeck Institute of Experimental Dermatology, University of L\u00fcbeck and University Clinic of Schleswig-Holstein","place":["L\u00fcbeck, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diamant","family":"Tha\u00e7i","sequence":"additional","affiliation":[{"name":"Institute for Inflammation Medicine, University of L\u00fcbeck","place":["L\u00fcbeck, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,31]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"102782","DOI":"10.1016\/j.eclinm.2024.102782","article-title":"GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review","volume":"75","author":"Alfaris","year":"2024","journal-title":"eClinicalMed"},{"key":"B2","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s40257-024-00911-x","article-title":"Obesity in hidradenitis suppurativa: are GLP-1 receptor agonists the new frontier?","volume":"26","author":"Strong","year":"2025","journal-title":"Am J Clin Dermatol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"6292","DOI":"10.3390\/jcm13216292","article-title":"The therapeutic potential of GLP-1 receptor agonists in the management of hidradenitis suppurativa: a systematic review of anti-inflammatory and metabolic effects","volume":"13","author":"Krajewski","year":"2024","journal-title":"J Clin Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/s41392-024-01931-z","article-title":"Glucagon-like peptide-1 receptor: mechanisms and advances in therapy","volume":"9","author":"Zheng","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"B5","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1055\/s-0043-1775966","article-title":"Dual GLP-1\/GIP agonist tirzepatide for diabetes and obesity: a review of the evidence","volume":"7","author":"Wardeh","year":"2024","journal-title":"J Diabetes Endocr Pract"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.2146\/ajhp150990","article-title":"Role of glucagon-like peptide 1 receptor agonists in management of obesity","volume":"73","author":"Isaacs","year":"2016","journal-title":"Am J Health Syst Pharm"},{"key":"B7","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1159\/000537920","article-title":"Questionnaire-based global prevalence of hidradenitis suppurativa: a systematic review and meta-analysis","volume":"241","author":"Zahid","year":"2025","journal-title":"Dermatology"},{"key":"B8","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.ijwd.2019.06.026","article-title":"Comorbidities of hidradenitis suppurativa: a review of the literature","volume":"5","author":"Cartron","year":"2019","journal-title":"Int J Womens Dermatol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1177\/12034754251320045","article-title":"GLP-1 Agonists in patients with hidradenitis suppurativa: a case series","volume":"29","author":"Rames","year":"2025","journal-title":"J Cutan Med Surg"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1016\/j.jaad.2025.06.077","article-title":"Glucagon-like peptide-1 receptor agonists in the adjunctive treatment of patients with hidradenitis suppurativa: a systematic review","volume":"93","author":"S\u00e1nchez-Feliciano","year":"2025","journal-title":"J Am Acad Dermatol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.jdcr.2024.02.023","article-title":"A case of recalcitrant hidradenitis suppurativa concomitantly treated with tirzepatide","volume":"52","author":"Chan","year":"2024","journal-title":"JAAD Case Rep"},{"key":"B12","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1016\/j.jaad.2025.11.017","article-title":"The impact of GLP-1 receptor agonists on clinical outcomes and healthcare utilization in hidradenitis suppurativa patients: a retrospective cohort study using TriNetX","volume":"94","author":"Fite","year":"2026","journal-title":"J Am Acad Dermatol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"e140","DOI":"10.1111\/jdv.20874","article-title":"GLP-1RAs and cardiovascular risk reduction in hidradenitis suppurativa: a real-world cohort study","volume":"40","author":"Chou","year":"2026","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.36849\/JDD.9569","article-title":"An open-label, single-center proof of concept study evaluating the efficacy and safety of tirzepatide for moderate to severe hidradenitis suppurativa","volume":"24","author":"Acosta-Madiedo","year":"2025","journal-title":"J Drugs Dermatol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1093\/bjd\/ljaf346","article-title":"GLP-1RA and reduced mortality, cardiovascular and psychiatric risks in psoriasis: a large-scale cohort study","volume":"194","author":"Olbrich","year":"2026","journal-title":"Br J Dermatol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"292","DOI":"10.2337\/dc24-1678","article-title":"Efficacy of GLP-1 receptor agonists on weight loss, BMI, and waist circumference for patients with obesity or overweight: a systematic review, meta-analysis, and meta-regression of 47 randomized controlled trials","volume":"48","author":"Wong","year":"2025","journal-title":"Diabetes Care"},{"key":"B17","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"B19","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1016\/j.jaad.2024.10.069","article-title":"No association between Adalimumab use and heart failure in patients with hidradenitis suppurativa: a propensity matched study","volume":"92","author":"Pakhchanian","year":"2025","journal-title":"J Am Acad Dermatol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1136\/annrheumdis-2014-206624","article-title":"The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis","volume":"74","author":"Roubille","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"B21","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1001\/jamadermatol.2026.1753","article-title":"Ixekizumab with or without tirzepatide in adults with psoriasis and overweight or obesity: a phase 3b randomized clinical trial","volume":"162","author":"Lebwohl","year":"2026","journal-title":"JAMA Dermatol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/art.70134","article-title":"Ixekizumab with tirzepatide achieved greater disease control than ixekizumab alone in adults with psoriatic arthritis and overweight or obesity: results from a randomized clinical trial","author":"Merola","year":"2026","journal-title":"Arthritis Rheumatol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1111\/ijd.17186","article-title":"Risk of cardiovascular disorders in hidradenitis suppurativa patients: a large-scale, propensity-matched global retrospective cohort study","volume":"63","author":"Krajewski","year":"2024","journal-title":"Int J Dermatol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"565","DOI":"10.4093\/dmj.2025.0681","article-title":"Glycemic improvement with low-dose dulaglutide is associated with leptin and obestatin modulation in type 2 diabetes Mellitus","volume":"50","author":"Jung","year":"2026","journal-title":"Diabetes Metab J"},{"key":"B25","doi-asserted-by":"publisher","first-page":"20420188231222367","DOI":"10.1177\/20420188231222367","article-title":"Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications","volume":"15","author":"Alharbi","year":"2024","journal-title":"Ther Adv Endocrinol Metab"},{"key":"B26","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1001\/jamapsychiatry.2025.0679","article-title":"Glucagon-like peptide 1 receptor agonists and mental health: a systematic review and meta-analysis","volume":"82","author":"Pierret","year":"2025","journal-title":"JAMA Psychiatry"},{"key":"B27","doi-asserted-by":"publisher","first-page":"614884","DOI":"10.3389\/fnbeh.2020.614884","article-title":"Can GLP-1 be a target for reward system related disorders? A qualitative synthesis and systematic review analysis of studies on palatable food, drugs of abuse, and alcohol","volume":"14","author":"Eren-Yazicioglu","year":"2021","journal-title":"Front Behav Neurosci"},{"key":"B28","doi-asserted-by":"publisher","first-page":"55353","DOI":"10.12775\/JEHS.2024.69.55353","article-title":"The impact of GLP-1 agonists on depression treatment: a literature review","volume":"69","author":"Lemieszek","year":"2024","journal-title":"J Educ Health Sport"},{"key":"B29","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1210\/en.2011-1443","article-title":"GLP-1 neurons in the nucleus of the solitary tract project directly to the ventral tegmental area and nucleus accumbens to control for food intake","volume":"153","author":"Alhadeff","year":"2012","journal-title":"Endocrinology"},{"key":"B30","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.physbeh.2013.04.003","article-title":"Role of central glucagon-like peptide-1 in stress regulation","volume":"122","author":"Ghosal","year":"2013","journal-title":"Physiol Behav"},{"key":"B31","doi-asserted-by":"publisher","first-page":"189","DOI":"10.3390\/life13010189","article-title":"Hidradenitis suppurativa burdens on mental health: a literature review of associated psychiatric disorders and their pathogenesis","volume":"13","author":"Caccavale","year":"2023","journal-title":"Life"},{"key":"B32","doi-asserted-by":"publisher","first-page":"23m15068","DOI":"10.4088\/JCP.23m15068","article-title":"Significant decrease in alcohol use disorder symptoms secondary to semaglutide therapy for weight loss: a case series","volume":"85","author":"Richards","year":"2023","journal-title":"J Clin Psychiatry"},{"key":"B33","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/s41591-023-02672-2","article-title":"Association of semaglutide with risk of suicidal ideation in a real-world cohort","volume":"30","author":"Wang","year":"2024","journal-title":"Nat Med"},{"key":"B34","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1111\/jdv.20694","article-title":"The effects of GLP-1RA on inflammatory skin diseases: a comprehensive review","volume":"39","author":"Paschou","year":"2025","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1089\/dia.2014.0188","article-title":"Gastrointestinal adverse events of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a systematic review and network meta-analysis","volume":"17","author":"Sun","year":"2015","journal-title":"Diabetes Technol Ther"},{"key":"B36","doi-asserted-by":"publisher","first-page":"4315","DOI":"10.3390\/molecules27134315","article-title":"Tirzepatide, a new era of dual-targeted treatment for diabetes and obesity: a mini-review","volume":"27","author":"Chavda","year":"2022","journal-title":"Molecules"},{"key":"B37","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.jaad.2018.01.014","article-title":"Prevalence of type 2 diabetes mellitus among patients with hidradenitis suppurativa in the United States","volume":"79","author":"Garg","year":"2018","journal-title":"J Am Acad Dermatol"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1909537\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T04:29:47Z","timestamp":1788150587000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1909537\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,31]]},"references-count":37,"alternative-id":["10.3389\/fmed.2026.1909537"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1909537","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,31]]},"article-number":"1909537"}}